Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0376358 (
prostate cancer
)
59,338
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The enzyme
deoxyhypusine hydroxylase
(
DOHH
) catalyzes the activation of eukaryotic translation initiation factor (eIF5A), a protein essential for cell growth. Using bioinformatic predictions and reporter gene assays, we have identified a 182-nt element within the
DOHH
3'-untranslated region (3'-UTR) that contains a number of target sites for miR-331-3p and miR-642-5p. Quantitative RT-PCR studies demonstrated overexpression of
DOHH
mRNA and underexpression of miR-331-3p and miR-642-5p in several
prostate cancer
cell lines compared with normal prostate epithelial cells. Transient overexpression of miR-331-3p and/or miR-642-5p in DU145
prostate cancer
cells reduced
DOHH
mRNA and protein expression and inhibited cell proliferation. We observed synergistic growth inhibition with the combination of miR-331-3p and miR-642-5p and mimosine, a pharmacological
DOHH
inhibitor. Finally, we identified a significant inverse relationship between the expression of miR-331-3p or miR-642-5p and
DOHH
in a cohort of human
prostate cancer
tissues. Our results suggest a novel role for miR-331-3p and miR-642-5p in the control of
prostate cancer
cell growth via the regulation of
DOHH
expression and eIF5A activity.
...
PMID:Regulation of expression of deoxyhypusine hydroxylase (DOHH), the enzyme that catalyzes the activation of eIF5A, by miR-331-3p and miR-642-5p in prostate cancer cells. 2290 21